Postmarketing safety profile of subcutaneous interferon beta-1a given 3 times weekly: A retrospective administrative claims analysis

Journal of Managed Care Pharmacy

Volumn 21, Issue 8, 2015, Pages 650-660

  Smith, Meredith Y ^a   Sabidó Espin, Meritxell ^c   Trochanov, Anton ^c   Samuelson, Mark ^b   Guedes, Sandra ^c   Corvino, Frank A ^d   Richy, Florent F ^c  

^a US Drug Safety Strategy and Science EMD Serono   (United States)

^b US Drug Safety and Quality Assurance EMD Serono   (United States)

^c MERCK KGAA   (Germany)

^d Genesis Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; CORTICOSTEROID; ALPHA INTERFERON; IMMUNOLOGIC FACTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTICLE; BACKACHE; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONVULSION; COORDINATION DISORDER; CORTICOSTEROID THERAPY; DEPRESSION; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; ERYTHEMA MULTIFORME; FEMALE; FLU LIKE SYNDROME; HEALTH CARE UTILIZATION; HEALTH STATUS; HUMAN; HYPERBILIRUBINEMIA; HYPERTHYROIDISM; HYPERTRANSAMINASEMIA; HYPESTHESIA; HYPOTHYROIDISM; INJECTION SITE NECROSIS; JAUNDICE; LEUKOPENIA; LIVER FAILURE; LYMPHADENOPATHY; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALAISE; MALE; MEDICATION COMPLIANCE; MULTIPLE SCLEROSIS; MUSCLE HYPERTONIA; MYALGIA; OBSERVATIONAL STUDY; POSTMARKETING SURVEILLANCE; PRESCRIPTION; RECURRENCE RISK; RETROSPECTIVE STUDY; RIGOR; SEIZURE; SOMNOLENCE; STEVENS JOHNSON SYNDROME; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; THORAX PAIN; THROMBOCYTOPENIA; TOXIC HEPATITIS; URINE INCONTINENCE; URTICARIA; XEROPHTHALMIA; XEROSTOMIA; DRUG ADMINISTRATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FACTUAL DATABASE; HEALTH INSURANCE; INSURANCE; MEDICARE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANAPHYLAXIS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE HEPATITIS; BONE PAIN; DRUG SURVEILLANCE PROGRAM; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HEALTH CARE; ICD-9-CM; INCIDENCE; INJECTION SITE REACTION; LIVER FUNCTION; LIVER INJURY; LUPUS LIKE SYNDROME; PANCYTOPENIA; RETINOPATHY; SIDE EFFECT; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID DISEASE; URINARY DYSFUNCTION; VISUAL DISORDER;

ADULT; DATABASES, FACTUAL; DRUG ADMINISTRATION SCHEDULE; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SUBCUTANEOUS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; INTERFERON-ALPHA; MALE; MEDICARE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PATIENT SAFETY; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 84938915217     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2015.21.8.650     Document Type: Article

References (38)

1. World Health Organization. Atlas: Multiple Sclerosis Resources in the World 2008. Geneva: WHO Press; 2008. Available at: http://whqlibdoc.who.int/publications/2008/9789241563758_eng.pdf?ua=1. Accessed June 16, 2015.
2. Fox RJ, Bethoux F, Goldman MD, Cohen JA. Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med. 2006;73(1):91-102.
3. Cross AH, Naismith RT. Established and novel disease-modifying treatments in multiple sclerosis. J Intern Med. 2014;275(4):350-63.
4. Rebif sales report. Company data on file. Merck KGaA. 2014.
5. PRISMS Study Group. Randomized double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-504.
6. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology. 2002;59(10):1496-506.
7. Rawlins MD. Spontaneous reporting of adverse drug reactions I: the data. Br J Clin Pharmacol. 1988;26(1):1-5.
8. Pozzilli C, Propserini L, Sbardella E, et al. Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience. Neurol Sci. 2005;26(Suppl 4):S174-78.
9. Río J, Tintoré M, Nos C, Téllez N, Galán I, Montalban X. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre. J Neurol. 2005;252(7):795-800.
10. Milanese C, La Mantia, Palumbo R, et al. A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis:different response in drop-outs and treated patients. J Neruol Neruosurg Psychiatry. 2003;74(12):1689-92.
11. Trojano M, Paolicelli D, Zimatore GB, et al. The INFbeta treatment of multiple sclerosis (MS) in clinical practice: the experience at the MS center of Bari Italy. Neurol Sci. 2005;26(Suppl 4):S179-82.
12. Paolillo A, Pozzilli C, Giugni, E, et al. A 6-year clinical and MRI followup study of patients with relapsing-remitting multiple sclerosis treated with interferon-beta. Eur J Neurol. 2002;9(6):645-55.
13. Twok S, Nippert I, Scherer P, Haas J, Pohlau D, Kugler J. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population. Curr Med Res Opin. 2007;23(6):1209-15.
14. Beer K, Müller M, Hew-Winzeler AM, et al. The prevalence of injectionsite reactions with disease-modifying therapies and their effect on adherence in patients with multiple sclerosis: an observational study. BMC Neurol. 2011;11:144. Available at: http://www.biomedcentral.com/1471-2377/11/144. Accessed June 16, 2015.
15. Tremlett HL, Yoshida EM, Oger J. Liver injury associated with the β-interferons for MS: a comparison between the three products. Neurology. 2004;62(4):628-31.
16. Limmroth V, Malessa R, Zettl UK, et al. Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis. J Neurol. 2007;254(1):67-77.
17. Etemadifar M, Janghorbani M, Shaygannejad V. Comparison of Betaferon, Avonex, and Rebif in treatment of relapsing-remitting multiple sclerosis. Acta Neurol Scand. 2006;113(5):283-87.
18. Bonavita S, Dinacci D, Lavorgna L, et al. Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project. Neurol Sci. 2006;27(Suppl 5): S365-68.
19. Koch-Henriksen N, Sørensen PS, Christensen T, et al. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006;66(7):1056-60.
20. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol. 2005;12(6);425-31.
21. Sorenson PS, Koch-Henriksen N, Rovnborg M, et al. Immunodulatory treatment of multiple sclerosis in Denmark: a prospective nationwide survey. Mult Scler. 2006;12(3):253-64.
22. Gobbi C, Zecca C, Linnebank M, et al. Swiss analysis of multiple sclerosis:a multicenter, non-interventional, retrospective cohort study of diseasemodifying therapies. Eur Neurol. 2013;70(1-2):35-41.
23. Hupperts R, Ghazi-Vissier L, Martins Silva A, et al. The STAR Study: a real-world, international, observational study of the safety and tolerability of, and adherence to, serum-free subcutaneous interferon β-1a in patients with relapsing multiple sclerosis. Clin Ther. 2014;36(12):1946-57.
24. U.S. Food and Drug Administration. FDA's Sentinel Initiative. November 21, 2014. Available at: http://www.fda.gov/Safety/FDAsSentinelinitiative/ucm2007250.htm. Accessed June 16, 2015.
25. REBIF (interferon beta-1a), for subcutaneous injection. EMD Serono, Inc. Revised March 2015. Available at: http://emdserono.com/cmg.emdserono_us/en/images/Rebif%20PI_Jun2014_tcm115_19765.pdf. Accessed June 16, 2015.
26. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47(11):1245-51.
27. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm. 2002;8(6):469-76. Available at: http://www.amcp.org/data/jmcp/Research-469-476.pdf.
28. Chastek BJ, Oleen-Burkey M, Lopez-Bresnahan MV. Medical chart validation of an algorithm for identifying multiple sclerosis relapse in healthcare claims. J Med Econ. 2010;13(4):618-25.
29. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50(1):105-16.
30. Bayas A, Rieckmann P. Managing the adverse effects of interferon beta therapy in multiple sclerosis. Drug Saf. 2000;22(2):149-59.
31. Patti F. Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence. Patient Prefer Adherence. 2010;4:1-9.
32. PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term tolerability of interferon beta-1a in relapsing MS. Neurology. 2001;56(12):1628-36.
33. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon-beta-1a in patients with relapsing-remitting MS. Neurology. 2006;67(6):944-53.
34. Mohr DC, Goodkin DE, Likosky W, et al. Treatment of depression improves adherence to interferon beta-1b therapy for multiple sclerosis. Arch Neurol. 1997;54(5):531-33.
35. Patten SB, Metz LM. Interferon-β and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler. 2001;7(4):243-48.
36. Rieckmann P, O'Connor P, Francis GS, Wetherill G, Alteri E. Haematological effects of interferon-β-1a (Rebif) therapy in multiple sclerosis. Drug Saf. 2004;27(10):745-56.
37. Francis GS, Grumser Y, Altieri E, et al. Hepatic reactions during treatment of multiple sclerosis with interferon-β-1a: incidence and clinical significance. Drug Saf. 2003;26(11):815-27.
38. Strom BL. Data validity issues in using claims data. Pharmacoepidemiol Drug Saf. 2001;10(5):389-92